ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Nikhil Lalwani Sells 5,400 Shares

Key Points

• CEO Nikhil Lalwani sold 5,400 ANI Pharmaceuticals shares at an average price of $71.89, generating $388,206. The transaction was conducted under a pre-arranged Rule 10b5-1 plan and reduced his direct holdings by 1.59% to 333,689 shares.
• ANI Pharmaceuticals reported quarterly earnings of $2.21 per share, exceeding estimates of $2.04, while revenue rose 25.8% year over year to $266.04 million. The company issued fiscal 2026 EPS guidance of $9.19 to $9.69.
• ANIP shares recently traded near $72.29, below the consensus analyst price target of $99.60. Analysts collectively rate the stock “Hold,” with three Buy ratings and four Hold ratings.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CEO Nikhil Lalwani sold 5,400 shares of the business's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $71.89, for a total value of $388,206.00. Following the completion of the transaction, the chief executive officer directly owned 333,689 shares of the company's stock, valued at approximately $23,988,902.21. This trade represents a 1.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nikhil Lalwani also recently made the following trade(s):

• On Tuesday, September 15th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $71.00, for a total transaction of $383,400.00.
• On Tuesday, August 25th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $74.30, for a total transaction of $401,220.00.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock traded up $0.01 during trading hours on Friday, reaching $72.29. The company had a trading volume of 333,921 shares, compared to its average volume of 382,196. The business has a fifty day moving average price of $73.71 and a 200-day moving average price of $78.01. ANI Pharmaceuticals, Inc. has a one year low of $69.58 and a one year high of $97.00. The firm has a market cap of $1.66 billion, a PE ratio of 15.58, a price-to-earnings-growth ratio of 2.26 and a beta of 0.50. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same quarter in the prior year, the firm earned $1.80 earnings per share. The firm's revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Oppenheimer assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 23rd. They set a "market perform" rating and a $85.00 target price for the company. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They issued an "outperform" rating and a $104.00 price target on the stock. Weiss Ratings cut shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, August 11th. Canaccord Genuity Group cut their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Finally, Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Three investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $99.60.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. KBC Group NV purchased a new stake in ANI Pharmaceuticals in the 1st quarter worth approximately $28,000. Versant Capital Management Inc boosted its position in shares of ANI Pharmaceuticals by 103.3% in the third quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company's stock worth $31,000 after purchasing an additional 217 shares during the period. Persistent Asset Partners Ltd purchased a new stake in shares of ANI Pharmaceuticals in the second quarter worth $76,000. State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals in the second quarter worth $86,000. Finally, GAMMA Investing LLC raised its position in shares of ANI Pharmaceuticals by 13.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,783 shares of the specialty pharmaceutical company's stock valued at $130,000 after purchasing an additional 211 shares during the period. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI's portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.